These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 24291241)

  • 1. Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study.
    Abrigo JM; Shen J; Wong VW; Yeung DK; Wong GL; Chim AM; Chan AW; Choi PC; Chan FK; Chan HL; Chu WC
    J Hepatol; 2014 Apr; 60(4):809-15. PubMed ID: 24291241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High resolution in vivo 31P-MRS of the liver: potential advantages in the assessment of non-alcoholic fatty liver disease.
    Jeon MJ; Lee Y; Ahn S; Lee C; Kim OH; Oh BC; Yu U; Kim H
    Acta Radiol; 2015 Sep; 56(9):1051-60. PubMed ID: 25270373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
    Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
    Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling.
    Sevastianova K; Hakkarainen A; Kotronen A; Cornér A; Arkkila P; Arola J; Westerbacka J; Bergholm R; Lundbom J; Lundbom N; Yki-Järvinen H
    Radiology; 2010 Aug; 256(2):466-73. PubMed ID: 20656836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances.
    Menon DK; Sargentoni J; Taylor-Robinson SD; Bell JD; Cox IJ; Bryant DJ; Coutts GA; Rolles K; Burroughs AK; Morgan MY
    Hepatology; 1995 Feb; 21(2):417-27. PubMed ID: 7843715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro hepatic phosphorus-31 magnetic resonance spectroscopy and electron microscopy in chronic ductopenic rejection of human liver allografts.
    Taylor-Robinson SD; Sargentoni J; Bell JD; Thomas EL; Marcus CD; Changani KK; Saeed N; Hodgson HJ; Davidson BR; Burroughs AK; Rolles K; Foster CS; Cox IJ
    Gut; 1998 May; 42(5):735-43. PubMed ID: 9659173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of early imaging response after chemoembolization of hepatocellular carcinoma by phosphorus-31 magnetic resonance spectroscopy-initial experience.
    Yuan Z; Ye XD; Dong S; Xu LC; Xiao XS
    J Vasc Interv Radiol; 2011 Aug; 22(8):1166-73. PubMed ID: 21703872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorus magnetic resonance spectroscopy in malformations of cortical development.
    Andrade CS; Otaduy MC; Valente KD; Maia DF; Park EJ; Valério RM; Tsunemi MH; Leite CC
    Epilepsia; 2011 Dec; 52(12):2276-84. PubMed ID: 21973076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease.
    Gonzalez RG; Guimaraes AR; Moore GJ; Crawley A; Cupples LA; Growdon JH
    Alzheimer Dis Assoc Disord; 1996; 10(1):46-52. PubMed ID: 8919496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy.
    Noren B; Dahlqvist O; Lundberg P; Almer S; Kechagias S; Ekstedt M; Franzén L; Wirell S; Smedby O
    Eur J Radiol; 2008 May; 66(2):313-20. PubMed ID: 17646074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profile of liver damage in non-cirrhotic virus C and autoimmune hepatitis: A proton decoupled
    Hakkarainen A; Puustinen L; Kivisaari R; Boyd S; Nieminen U; Arkkila P; Lundbom N
    Eur J Radiol; 2017 May; 90():205-211. PubMed ID: 28583636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorus-31 MR spectroscopy in pediatric liver transplant recipients: a noninvasive assessment of graft status with correlation with liver function tests and liver biopsy.
    Chu WC; Lam WW; Lee KH; Yeung DK; Sihoe J; Yeung CK
    AJR Am J Roentgenol; 2005 May; 184(5):1624-9. PubMed ID: 15855128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models.
    Jalan R; Sargentoni J; Coutts GA; Bell JD; Rolles K; Burroughs AK; Taylor Robinson SD
    Gut; 1996 Jul; 39(1):141-6. PubMed ID: 8881826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytochrome P450 induction on phosphorus metabolites and proton relaxation times measured by in vivo 31P-magnetic resonance spectroscopy and 1H-magnetic resonance relaxometry in human liver.
    Block W; Reichel C; Träber F; Skodra T; Lamerichs R; Kreft B; Spengler U; Sauerbruch T; Schild HH
    Hepatology; 1997 Dec; 26(6):1587-91. PubMed ID: 9398002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes of 3-tesla 31P-MR spectroscopy of bone and soft tissue tumors].
    Qi ZH; Li CF; Ma XX; Li ZF; Zhang K; Yu DX
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):442-6. PubMed ID: 19950555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.